Pricing Log in Create free account

Phathom Pharmaceuticals, Inc. (PHAT) vs Relmada Therapeutics, Inc. (RLMD)

Phathom Pharmaceuticals, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Phathom Pharmaceuticals, Inc. and Relmada Therapeutics, Inc. are of similar size ($413.0M and $402.1M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −30.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Phathom Pharmaceuticals, Inc. leads on 7 and Relmada Therapeutics, Inc. on 5.

Valuation

Metric PHAT RLMD Biotechnology median
P/E n/m n/m 10.60
P/S 1.62 n/m 9.40
P/B n/m 2.12 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.58 n/m 9.02
Earnings yield (19.76%) (24.49%) (32.88%)
Free cash flow yield (4.74%) (29.06%) (23.13%)

Profitability

Metric PHAT RLMD Biotechnology median
Gross margin 80.68% 0.00% 68.51%
Operating margin (9.26%) 0.00% 0.00%
Net margin (30.19%) 0.00% 0.00%
Free cash flow margin (7.65%) 0.00% 0.00%
Return on equity 21.55% (55.66%) (51.96%)
Return on assets (28.36%) (51.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PHAT RLMD Biotechnology median
Revenue growth (TTM) 86.75% — 6.76%
EPS growth (last fiscal year) 42.72% 45.28% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PHAT RLMD Biotechnology median
Debt to equity (0.48) 0.00 0.00
Current ratio 1.76 29.52 4.97
Net debt to EBITDA (0.51) 1.57 1.01

Dividend

Metric PHAT RLMD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PHAT RLMD Biotechnology median
Market cap 412.96m 402.14m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack